Types of Cancer We Treat

Leukemia in Adults

Our experts use the latest techniques to diagnose and treat all forms of blood cancer, including leukemia, in which the abnormal growth of white blood cells causes cancer. We also treat neoplastic blood diseases, including myeloproliferative disorders and myelodysplastic syndromes, all of which are caused by an excessive growth of blood cells.

Through a collaborative approach, our multidisciplinary team of hematologists, oncologists, and pathologists provides personalized care and creates a treatment plan based on your particular diagnosis and individual needs.

To achieve the best possible outcomes, we offer the latest treatments, including chemotherapy, targeted therapy, stem cell transplants, epigenetic treatments, immunotherapy, and radiation therapy. Through clinical trials, our translational research program offers access to innovative treatments to patients. Our experts also work in close partnership with our Blood and Marrow Transplant Program to provide multiple treatment options.

Find a Doctor & Schedule
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Hairy Cell Leukemia
Myelodysplastic Syndromes
Myeloproliferative Disorders

Related News

Scientists Define the Role for a Set of Bone Marrow Cells
Read Story
Perlmutter Cancer Center Receives Anonymous $75 Million Gift
Read Story

Clinical Trials and Research Studies

Phase 3

AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Learn More

Phase 3

AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Learn More

Phase 2

Open-label Multicenter Phase 2 Study Evaluating the Efficacy & Safety of Daratumumab in Pediatric & Young Adult Subjects =1 & =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Learn More

Phase 3

EA9161: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Learn More
View All Related Clinical Trials (10)